[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635496":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":37,"studyPopulation":11,"armGroups":38,"interventions":52,"overallOfficials":65,"centralContacts":69,"locations":77,"responsibleParty":110,"collaborators":112,"id":115,"slug":11,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":11,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":11,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":80,"whyStopped":11,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Part A: Percentage recovery from baseline in serum AGT",null,"Up to Day 4",{"measure":14,"description":11,"timeFrame":15},"Part B: Percentage recovery from baseline in mean seated office SBP","At Day 4 and Day 7",[17,20,22,24],{"measure":18,"description":11,"timeFrame":19},"Both Parts: Frequency of Adverse Events (AEs)","Up to 10 months",{"measure":10,"description":11,"timeFrame":21},"Up to Day 7",{"measure":23,"description":11,"timeFrame":15},"Part B: Percentage recovery from baseline in serum AGT",{"measure":25,"description":11,"timeFrame":15},"Part B: Change from baseline in mean seated office SBP",{"allocation":27,"interventionModel":28,"interventionModelDescription":11,"primaryPurpose":29,"observationalModel":11,"timePerspective":11,"maskingInfo":30},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":11,"whoMasked":32},"QUADRUPLE",[33,34,35,36],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","This study will be conducted in 2 parts:\n\n* Part A: Single dose (SD), dose-ranging part in adults with mild to moderate hypertension.\n* Part B: SD in adults with mild to moderate hypertension.",[39,46],{"label":40,"type":41,"description":42,"interventionNames":43},"ALN-AGT1 RVR","EXPERIMENTAL","Participants will be administered a single dose of zilebesiran followed by a single dose of ALN-AGT01 RVR.",[44,45],"Drug: ALN-AGT01 RVR","Drug: Zilebesiran",{"label":47,"type":48,"description":49,"interventionNames":50},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of zilebesiran followed by a single dose of placebo.",[51,45],"Drug: Placebo",[53,58,61],{"type":54,"name":55,"description":56,"armGroupLabels":57,"otherNames":11},"DRUG","ALN-AGT01 RVR","ALN-AGT01 RVR will be administered subcutaneously (SC)",[40],{"type":54,"name":47,"description":59,"armGroupLabels":60,"otherNames":11},"Placebo will be administered SC",[47],{"type":54,"name":62,"description":63,"armGroupLabels":64,"otherNames":11},"Zilebesiran","Zilebesiran will be administered SC",[40,47],[66],{"name":67,"affiliation":5,"role":68},"Medical Director","STUDY_DIRECTOR",[70,75],{"name":71,"role":72,"phone":73,"phoneExt":11,"email":74},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":71,"role":72,"phone":76,"phoneExt":11,"email":74},"1-877-256-9526",[78,92,101],{"facility":79,"status":80,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":11},"Clinical Trial Site","RECRUITING","Lake Forest","California","92630","United States","US",{"type":87,"coordinates":88},"Point",[89,90],-117.68922,33.64697,{"lat":90,"lon":89},{"facility":79,"status":80,"city":93,"state":94,"zip":95,"country":84,"countryCode":85,"cosmosGeoPoint":96,"geoPoint":100,"contacts":11},"Tampa","Florida","33613",{"type":87,"coordinates":97},[98,99],-82.45843,27.94752,{"lat":99,"lon":98},{"facility":79,"status":80,"city":102,"state":103,"zip":104,"country":84,"countryCode":85,"cosmosGeoPoint":105,"geoPoint":109,"contacts":11},"Savannah","Georgia","31405",{"type":87,"coordinates":106},[107,108],-81.09983,32.08354,{"lat":108,"lon":107},{"type":111,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[113],{"name":114,"class":6},"Hoffmann-La Roche","100635496",false,"NCT07553442","A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","Part A: Inclusion Criteria\n\n* Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg\n* Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications\n\nPart B: Inclusion Criteria\n\n* Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg\n* Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and\u002For thiazide\u002Fthiazide-like diuretic (if taking) for at least 3 weeks\n\nBoth Parts: Exclusion Criteria\n\n* Has known secondary hypertension or serum potassium more than 5 mmol\u002FL\n* Has an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73m\\^2\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","ALL","18 Years","75 Years",{"count":125,"type":126},93,"ESTIMATED","INTERVENTIONAL",[129],"PHASE2","The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.",[132],"Hypertension",[134,135,136,62,137],"RNAi therapeutic","oligonucleotide","Reversir","ALN-AGT01","2026-06-10",{"date":140,"type":141},"2026-06-12","ACTUAL",{"date":143,"type":141},"2026-04-27",{"date":145,"type":126},"2028-10-01",{"name":5,"class":6},3]